literature

HBV mutation literature information.

Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.

PMID: 33333207 2021 Journal of hepatology

Abstract: E-CFCP also reduced HBVETV-RL180M/S202G/M204V-viremia by 2 logs over 2 weeks, while ETV completely failed to reduce HBVETV-RL180M/S202G/M204V-viremia.

Abstract: E-CFCP's 4'-cyano and fluorine interact with both HBVWT-RT and HBVETV-RL180M/S202G-M204 -RT via Van der Waals and polar forces, being important for E-CFCP-triphosphate's interactions and anti-HBV potency.

Abstract: RESULTS: E-CFCP potently blocked HBVWTD1 production (IC50qPCR_cell=1.8 nM) in HepG2.2.15 cells and HBVWTC2 (IC50SB_cell=0.7 nM), entecavir (ETV)-resistant HBVETV-RL180M/S202G/

COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B.

PMID: 32708399 2020 Diagnostics (Basel, Switzerland)

Result: Among the two later cases, there were 3 classical mt including rtM204V/I (primary drug resistance mt) and rtL180M (compensatory/secondary mt).

Result: Multiple-point mt associated with LMV or ADF resistance were observed in 9 cases (6.3%), 6 cases carried double mt (rtV207M + rtS213T; rtV207M + rtL229V; rtV207M + rtI233V; rtV207I +

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

PMID: 32080249 2020 Scientific reports

Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.

Introduction: The amino acid substitutions, M204V/I and M204V/I + L180M, in HBV RT are known to cause 3TC resistance, and these mutations significantly reduce ETV effectiveness against HBV, thereby increasing the likelihood of subsequently developing greater ETV resistance through getting additional amino acid substitutions such as S202G in HBV RT.

Result: The corresponding M204V/I mutation in HBV RT has

7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.

PMID: 32084506 2020 Antiviral research

Abstract: Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the production of HBVWT (IC50 = 153.7 nM), entecavir (ETV)-resistant HBV carrying L180M/S202G/M204V substitutions (HBVETVR; IC50 = 373.2 nM), and adefovir dipivoxil (ADV)-resistant HBV carrying A181T/N236T substitutions (HBVADVR; IC50=192.6 nM), whereas ETV and ADV were less potent against HBVETVR and HBVADVR (IC50: >1,000 and 4,02

Result: We then analyzed the interactions of ETV-TP and CdFA-TP with HBV-RT, in which three amino acid substitutions associated with HBV's resistance to ETV (L180M/S202G/M204V) have been introduced (RTETV-R).

Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.

PMID: 32216026 2020 Liver international

Abstract: RESULTS: The rtL180M + rtM204V mutations were common among all the clones analysed.

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.

PMID: 32545313 2020 Viruses

Abstract: Several lamivudine-associated HBV resistance mutations, including L180M, A181T, M204I, and M204V, were observed.

Result: Analysis of polymerase gene sequences from baseline and follow-up samples showed the presence of resistance-associated mutations in 5 of these 6 patients, including L180M, A181T, M204I, and M20

Discussion: The current study also detected the M204I variant at baseline in treatment-naive patients, and other mutations such as A181T, L180M, or M204V during follow-up of individuals on a lamivudine-based regimen.

Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues.

PMID: 32765014 2020 Infection and drug resistance

Abstract: Primary and secondary DR variants were found in 7.3% (15/206) of patients, including rtL80I/V, rtI169T,

Result: Primary and/or secondary DR variants were found in 7.3% (15/206) of patients, and included rtL80I/V, rtI169T, rtV173L, rtL180M, rtA181T/V, rtM204I/V, and rtN236T.

Table: L180M

Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.

PMID: 32915862 2020 PloS one

Abstract: Resistance mutations included rtL80I, rtV173L, rtL180M, rtM204I/V and the overlapping sE164D, sW182*, sI195M and sW196LS variants.

Result: Amino acid changes including rtL80I, rtV173L, rtL180M,

Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations.

PMID: 32994690 2020 World journal of gastroenterology

Discussion: A phylogenetic analysis of Patient A-derived viral strains showed that sA159V+rtM204I (rtL180M) and sA159V+rtM204V (rtL180M) mutants are likely derived from the sA159V mutant as an adaptation to LAM pressure.

Discussion: The sA159V+rtL180M+rtT184L+rt

Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients.

PMID: 33124952 2020 Emerging microbes & infections

Result: Five AA sites identified with the significantly elevated entropy levels were rtL180M, rtA181T/V/I, rtM204I/V/L, rtL229V/M/F, rtN236T/I, four of which had been widely known already as classical resistance mutation.

Result: Only 1.1% (3 of 285, rtA181T/rtM204V/rtL180M + rtM204I) of HBV isolates harboring classica

Browser Board

Co-occurred Entities

Filtrator